{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.4.3.11. Record AECOPD severity and AECOPD end', 'date', '53', '6.4.3.12.', 'Recording of AE/SAEs', '53', '6.4.4.', 'Sampling', '53', '6.4.4.1.', 'Sputum Sampling', '53', '6.4.4.2.', 'Blood Sampling', '54', '6.4.5.', 'Health Related Quality of Life questionnaires', '54', '6.4.6.', 'Recording of AEs/SAEs', '54', '6.4.7.', 'Study conclusion', '54', '6.5.', 'Biological sample handling and analysis', '54', '6.5.1.', 'Use of specified study materials', '55', '6.5.2.', 'Biological samples', '55', '6.5.3.', 'Laboratory assays (Amended 19 October 2018)', '56', '7. SAFETY', '59', '7.1.', 'Safety definitions', '59', '7.1.1.', 'Definition of an adverse event (Amended 19 October', '2018)', '59', '7.1.2.', 'Definition of a serious adverse event', '59', '7.1.3.', 'Clinical laboratory parameters and other abnormal', 'assessments qualifying as AEs or SAEs', '60', '7.2.', 'Detecting and recording AEs, SAEs', '61', '7.2.1.', 'Time periods for detecting and recording AEs and SAEs', '61', '7.2.2.', 'Evaluation of SAEs (Amended 19 October 2018)', '62', '7.2.2.1.', 'Active questioning to detect SAEs', '62', '7.2.2.2.', 'Assessment of causality', '62', '7.2.2.3.', 'Assessment of outcomes', '63', '7.3.', 'Reporting of SAEs', '63', '7.3.1.', 'Prompt reporting of SAEs related to study participation to', 'GSK', '63', '7.3.2.', 'Contact information for reporting SAEs to GSK', '63', '7.3.3.', 'Completion and transmission of SAEs reports related to', 'study participation to GSK', '64', '7.3.3.1.', 'Back-up system in case the electronic reporting', 'system does not work', '64', '7.3.4.', \"Updating of SAE after freezing of the subject's eCRF\", '64', '7.3.5.', 'Regulatory reporting requirements for SAEs', '64', '7.4.', 'Treatment of AEs', '65', '8.', 'SUBJECT COMPLETION AND WITHDRAWAL', '65', '8.1.', 'Subject completion', '65', '8.2.', 'Subject withdrawal', '65', '9.', 'STATISTICAL METHODS', '66', '9.1.', 'Endpoints', '66', '9.1.1.', 'Primary endpoint (Amended 19 October 2018)', '66', '9.1.2.', 'Secondary endpoints', '66', '9.1.3.', 'Tertiary endpoints', '67', '9.2.', 'Determination of sample size', '67', '9.3.', 'Cohorts for Analyses', '68', '9.3.1.', 'All screened Set', '68', '9.3.2.', 'All Enrolled Set', '68', '19-OCT-2018', '15', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '9.3.3.', 'Full Analysis Set', '69', '9.4.', 'Analysis of demographics', '69', '9.5.', 'Analysis of primary objective', '69', '9.6.', 'Analysis of secondary objectives', '70', '9.7.', 'Analysis of tertiary objectives', '71', '9.8.', 'Conduct of analyses', '71', '9.8.1.', 'Sequence of analyses', '71', '9.8.2.', 'Statistical considerations for interim analyses', '71', '10. ADMINISTRATIVE MATTERS', '72', '10.1.', 'Electronic Case Report Form instructions', '72', '10.2.', 'Study monitoring by GSK Biologicals', '72', '10.3.', 'Record retention', '73', '10.4.', 'Quality assurance', '73', '10.5.', 'Posting of information on publicly available registers and publication', 'policy', '74', '10.6.', 'Provision of study results to investigators', '74', '10.7.', 'Data Sharing', '74', '11. COUNTRY SPECIFIC REQUIREMENTS', '74', '12. REFERENCES', '75', '19-OCT-2018', '16', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}